why choose us

First received: January 26, 2026

Clinical Trial: The Effect of Sacubitril and Valsartan on Heart Function in Chronic Hemodialysis Patients With HFpEF

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Heart Failure With Preserved Ejection Fraction (HFPEF)
Hemodialysis
Sacubitril/Valsartan

Study Type: INTERVENTIONAL


Official Title: The Effect of Sacubitril and Valsartan on Heart Function in Chronic Hemodialysis Patients With HFpEF

Brief Summary: Heart failure is the most common cause of death of patients on chronic hemodialysis treatment, and to date there is no effective therapy for the treatment of this comorbidity in this group of patients. The most common form of heart failure in these groups of patients is heart failure with preserved ejection fraction (HFpEF). As a new therapy for heart failure, a new group of drugs called angiotensin receptor and neprilysin inhibitors (ARNI) has been imposed, whose representative is the drug sacubitril/valsartan.…

Read more